Genzyme Sues To Stop Generic Leukemia Treatment

Law360, New York (July 30, 2012, 7:38 PM EDT) -- Genzyme Corp. filed a lawsuit in New Jersey on Friday seeking to block specialty pharmaceutical company Abon Pharmaceuticals LLC's plans to develop a generic version of Genzyme’s injectable leukemia chemotherapy drug Clolar.

Genzyme says Abon — a small drug development company specializing in drug delivery research and product development — has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for a treatment that infringes U.S. Patent Number 5,661,136, licensed to Genzyme co-plaintiff Southern Research Institute. Abon has denied the validity of...
To view the full article, register now.